Aerie Pharmaceuticals to Acquire Avizorex Pharma to Expand its Footprint in Ophthalmology

 Aerie Pharmaceuticals to Acquire Avizorex Pharma to Expand its Footprint in Ophthalmology

Aerie Pharmaceuticals to Acquire Avizorex Pharma to Expand its Footprint in Ophthalmology

Shots:

  • Aerie to acquire Avizorex (AVX) in an all-cash transaction. Avizorex to receive $10M up front, development & regulatory milestones with royalties in sales of the approved product in its development pipeline. The acquisition is expected to be close in H2’19
  • Aerie to get rights to acquire Avizorex’s lead candidate AVX-012 along with other compounds targeting TRPM8. The acquisition will foster Aerie’s dry eye product portfolio with the addition of Avizorex’s AVX-012.
  •  AVX-012 is a potent and selective agonist of the TRPM8 ion channel, acts by restoring the tear film stability and reduce discomfort in patients with dry eye, supported by P-IIa study to treat signs and symptoms of dry eye with its anticipated onset of P-IIb study in H2’2020

Click here to­ read full press release/ article | Ref: Businesswire | Image: AVX Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post